Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC
Results from ASCO 23 provide confidence that adjuvant osimertinib should be considered the standard of care for patients with resected EGFRm stage IB–IIIA NSCLC.
